Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ICCM NASDAQ:NVNO NASDAQ:QTI NASDAQ:SURG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeICCMIceCure Medical$0.81+0.9%$0.97$0.53▼$1.66$55.99M0.31959,253 shs140,557 shsNVNOenVVeno Medical$0.72-0.8%$1.09$0.67▼$5.62$13.76M0.94378,787 shs110,423 shsQTIQT Imaging$2.13-3.0%$2.36$0.35▼$0.84$57.71M-0.2183,964 shs19,969 shsSURGSurgePays$2.69-1.5%$2.73$1.05▼$3.47$55.04M0.43593,003 shs4,311 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceICCMIceCure Medical+1.47%-2.45%-23.29%-24.72%+46.45%NVNOenVVeno Medical+1.52%-8.40%-24.41%-85.47%-78.22%QTIQT Imaging-2.99%-1.53%-18.19%+13.14%+208.71%SURGSurgePays-1.09%0.00%-7.77%-7.14%+55.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeICCMIceCure Medical$0.81+0.9%$0.97$0.53▼$1.66$55.99M0.31959,253 shs140,557 shsNVNOenVVeno Medical$0.72-0.8%$1.09$0.67▼$5.62$13.76M0.94378,787 shs110,423 shsQTIQT Imaging$2.13-3.0%$2.36$0.35▼$0.84$57.71M-0.2183,964 shs19,969 shsSURGSurgePays$2.69-1.5%$2.73$1.05▼$3.47$55.04M0.43593,003 shs4,311 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceICCMIceCure Medical+1.47%-2.45%-23.29%-24.72%+46.45%NVNOenVVeno Medical+1.52%-8.40%-24.41%-85.47%-78.22%QTIQT Imaging-2.99%-1.53%-18.19%+13.14%+208.71%SURGSurgePays-1.09%0.00%-7.77%-7.14%+55.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceICCMIceCure Medical 2.60Moderate Buy$2.64224.11% UpsideNVNOenVVeno Medical 1.50ReduceN/AN/AQTIQT Imaging 0.00N/AN/AN/ASURGSurgePays 2.00Hold$9.50253.16% UpsideCurrent Analyst Ratings BreakdownLatest NVNO, SURG, QTI, and ICCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ICCMIceCure MedicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025NVNOenVVeno MedicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SURGSurgePaysWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/7/2025ICCMIceCure MedicalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.00 ➝ $2.5010/3/2025SURGSurgePaysAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $9.509/27/2025ICCMIceCure MedicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025NVNOenVVeno MedicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SURGSurgePaysWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/21/2025NVNOenVVeno MedicalLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/15/2025ICCMIceCure MedicalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$2.50 ➝ $2.008/15/2025ICCMIceCure MedicalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookICCMIceCure Medical$2.79M20.04N/AN/A$0.12 per share6.78NVNOenVVeno MedicalN/AN/AN/AN/A$2.40 per shareN/AQTIQT Imaging$4.00M14.44N/AN/A($1.91) per share-1.11SURGSurgePays$36.46M1.51N/AN/A$0.76 per share3.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateICCMIceCure Medical-$15.32M-$0.16N/AN/AN/A-317.62%-136.96%-71.46%11/25/2025 (Estimated)NVNOenVVeno Medical-$21.82M-$1.20N/AN/AN/AN/A-57.35%-53.49%10/29/2025 (Estimated)QTIQT Imaging-$4.03MN/A0.00∞N/AN/AN/A-65.94%11/11/2025 (Estimated)SURGSurgePays-$45.73M-$2.49N/AN/AN/A-133.85%-333.87%-195.36%11/11/2025 (Estimated)Latest NVNO, SURG, QTI, and ICCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025SURGSurgePays-$0.17N/AN/AN/A$18.12 millionN/A8/13/2025Q2 2025ICCMIceCure Medical-$0.06$0.06+$0.12$0.06$0.90 million$0.66 million8/13/2025Q2 2025SURGSurgePays-$0.31-$0.36-$0.05-$0.36$16.14 million$11.52 million7/31/2025Q2 2025NVNOenVVeno Medical-$0.28-$0.33-$0.05-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthICCMIceCure MedicalN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/AQTIQT ImagingN/AN/AN/AN/AN/ASURGSurgePaysN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioICCMIceCure Medical0.021.180.88NVNOenVVeno MedicalN/A11.8111.81QTIQT ImagingN/A1.060.48SURGSurgePays101.871.110.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipICCMIceCure Medical0.62%NVNOenVVeno Medical34.71%QTIQT Imaging24.19%SURGSurgePays6.94%Insider OwnershipCompanyInsider OwnershipICCMIceCure Medical2.44%NVNOenVVeno Medical16.00%QTIQT Imaging75.40%SURGSurgePays30.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableICCMIceCure Medical6068.70 million67.02 millionNot OptionableNVNOenVVeno Medical3019.25 million16.17 millionOptionableQTIQT ImagingN/A27.13 million6.68 millionN/ASURGSurgePays4020.43 million14.20 millionOptionableNVNO, SURG, QTI, and ICCM HeadlinesRecent News About These CompaniesSurgePays (NASDAQ:SURG) Stock Crosses Above 200-Day Moving Average - Should You Sell?October 17, 2025 | marketbeat.comSurgePays Announces Sequential Revenue Growth of Over 60% for Q3 and Affirms 2026 Revenue Guidance of $225 MillionOctober 16, 2025 | prnewswire.comSurgePays (NASDAQ:SURG) Shares Pass Above 200 Day Moving Average - What's Next?October 10, 2025 | marketbeat.comWeiss Ratings Reaffirms "Sell (E+)" Rating for SurgePays (NASDAQ:SURG)October 9, 2025 | marketbeat.comSurgePays (NASDAQ:SURG) Price Target Raised to $9.50 at Ascendiant Capital MarketsOctober 3, 2025 | marketbeat.comSurgepays Unveils Growth Strategy Amid Stock VolatilityOctober 2, 2025 | aktiencheck.deASurgePays CFO Anthony Evers to Depart by Year-EndOctober 2, 2025 | tipranks.comThomas Hughes | Page 3September 25, 2025 | entrepreneur.comESurgePays (NASDAQ:SURG) Stock Passes Above Two Hundred Day Moving Average - What's Next?September 25, 2025 | marketbeat.com8 Most Undervalued Telecom Stocks to Invest InSeptember 11, 2025 | insidermonkey.comMarket Basket Food Stores Rolls Out Digital Advertising PlatformAugust 28, 2025 | csnews.comCSurgePays Launches ClearLine Across All Market Basket Stores, Driving High-Margin Recurring SaaS Revenue Through Nationwide Retail Media RolloutAugust 28, 2025 | prnewswire.comPhone-in-a-Box Prepaid Service SmartphonesAugust 25, 2025 | csnews.comCAnalysts Have Lowered Expectations For SurgePays, Inc. (NASDAQ:SURG) After Its Latest ResultsAugust 16, 2025 | finance.yahoo.comSurgePays Second Quarter 2025 Earnings: Misses ExpectationsAugust 15, 2025 | finance.yahoo.comSurgePays sees 2025 revenue $75M-$90M vs. $15.09M in 2024August 15, 2025 | msn.comSurgePays Reports Growth and Sets Ambitious Revenue TargetsAugust 14, 2025 | msn.comSurgePays, Inc. (NASDAQ:SURG) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | insidermonkey.comSurgePays, Inc. (SURG) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | seekingalpha.comSurgePays, Inc. (SURG) Reports Q2 Loss, Lags Revenue EstimatesAugust 13, 2025 | zacks.comSurgePays Accelerates Growth Across All Business Verticals; Reports Q2 2025 Results and Issues Revenue Guidance of $75M to $90M in 2025 and $225M to $240M in 2026August 13, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Defense Stocks Surging as Ukraine Tensions DeepenBy Dan Schmidt | October 5, 2025Alphabet: After Its Best Quarter in Decades, Is It Time to Buy?By Ryan Hasson | October 3, 2025Lithium Americas Stock Exploded Last Week—Here’s WhyBy Jordan Chussler | October 1, 2025Why Congress Is Buying Intuitive Surgical Ahead of EarningsBy Gabriel Osorio-Mazilli | October 14, 2025The Juice Is Loose: Why Plug Power's Rally Is Just the BeginningBy Jeffrey Neal Johnson | October 7, 2025NVNO, SURG, QTI, and ICCM Company DescriptionsIceCure Medical NASDAQ:ICCM$0.81 +0.01 (+0.93%) As of 10:05 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.enVVeno Medical NASDAQ:NVNO$0.72 -0.01 (-0.82%) As of 10:04 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. QT Imaging NASDAQ:QTI$2.13 -0.07 (-2.99%) As of 10/22/2025QT Imaging Holdings, Inc. engages in the research, development, and commercialization of body imaging systems for detection, diagnosis, monitoring, and treatment of diseases. The company offers QT Ultrasound Breast Scanner, an ultrasonic imaging system that provides reflection-mode and transmission-mode images of a patient's breast. QT Imaging Holdings, Inc. was founded in 2011 and is based in Novato, California.SurgePays NASDAQ:SURG$2.69 -0.04 (-1.47%) As of 10:00 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.SurgePays, Inc., together with its subsidiaries, operates as a financial technology and telecom company in the United States. It operates through three segments: Mobile Virtual Network Operators, Comprehensive Platform Services, and Lead Generation. The company offers subsidized and non-subsidized mobile virtual network operators for internet connectivity through mobile broadband services to consumers; ACH banking relationships and fintech transactions platform to convenience stores; wireless top-up transactions and wireless product aggregation; and lead generation and case management solutions primarily to law firms in the mass tort industry, as well as call center activities. SurgePays, Inc. is headquartered in Bartlett, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
